{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:20:34Z","timestamp":1792149634945,"version":"4.4.0"},"reference-count":176,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.pharmthera.2004.07.004","type":"journal-article","created":{"date-parts":[[2004,9,14]],"date-time":"2004-09-14T18:27:57Z","timestamp":1095186477000},"page":"223-243","source":"Crossref","is-referenced-by-count":53,"title":["Emerging roles of urotensin-II in cardiovascular disease"],"prefix":"10.1016","volume":"103","author":[{"given":"Fraser D.","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2004.07.004_bib1","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/45809","article-title":"Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14","volume":"401","author":"Ames","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1042\/CS20030037","article-title":"Cutaneous vascular reactivity is reduced in aging and in heart failure: association with inflammation","volume":"105","author":"Andersson","year":"2003","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib3","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/01.CIR.102.22.2781","article-title":"Primary pulmonary hypertension: a vascular biology and translational research \u201cwork in progress\u201d","volume":"102","author":"Archer","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjp.0705254","article-title":"Deletion of the UT receptor gene results in the selective loss of urotensin II contractile activity in aortae isolated from UT receptor knockout mice","volume":"139","author":"Behm","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00210-004-0873-1","article-title":"Urotensin II: a novel systemic hypertensive factor in the cat","volume":"369","author":"Behm","year":"2004","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1471-4892(03)00004-3","article-title":"Fostering orphan receptors: an indispensable role for integrative, in vivo, haemodynamic studies","volume":"3","author":"Bennett","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/thx.2003.011197","article-title":"Vasoconstrictive effects of endothelin-1, endothelin-3, and urotensin II in isolated perfused human lungs and isolated human pulmonary arteries","volume":"59","author":"Bennett","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.bjp.0704448","article-title":"Urotensin II evokes potent vasoconstriction in humans in vivo","volume":"135","author":"B\u00f6hm","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib9","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.bjp.0703513","article-title":"Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries","volume":"130","author":"Bottrill","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1042\/bj20021566","article-title":"Photolabelling the rat urotensin II\/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain","volume":"370","author":"Boucard","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1124\/jpet.103.052415","article-title":"Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay","volume":"306","author":"Brkovic","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/01.CIR.0000102381.57477.50","article-title":"Endothelial dysfunction in pulmonary hypertension","volume":"109","author":"Budhiraja","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00059-002-2354-y","article-title":"Cardiac fibrosis as a cause of diastolic dysfunction","volume":"27","author":"Burlew","year":"2002","journal-title":"Herz"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib14","first-page":"449","article-title":"Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670","volume":"292","author":"Burrell","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00210-001-0503-0","article-title":"Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents","volume":"365","author":"Camarda","year":"2002","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1097\/01.hjh.0000125452.28861.f1","article-title":"Plasma concentration of urotensin II is raised in hypertension","volume":"22","author":"Cheung","year":"2004","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib176","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.104.068320","article-title":"Pharmacology of the urotensin-II receptor antagonist Act-058362: First demonstration of a pathophysiological role of the urotensin system","author":"Clozel","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pharmthera.2004.07.004_bib17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/(SICI)1097-010X(19960601\/15)275:2\/3<226::AID-JEZ14>3.0.CO;2-H","article-title":"Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates","volume":"275","author":"Conlon","year":"1996","journal-title":"J Exp Zool"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib18","doi-asserted-by":"crossref","first-page":"15803","DOI":"10.1073\/pnas.95.26.15803","article-title":"Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord","volume":"95","author":"Coulouarn","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0014-5793(99)01003-0","article-title":"Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors","volume":"457","author":"Coulouarn","year":"1999","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib20","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0008-6363(99)00150-9","article-title":"Lipids and the endothelium","volume":"43","author":"Dart","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199800001-00002","article-title":"Endothelin-converting enzyme in the human vasculature: evidence for differential conversion of big endothelin-3 by endothelial and smooth muscle cells","volume":"31","author":"Davenport","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0014-5793(95)00249-9","article-title":"Processing of proendothelin-1 by human furin convertase","volume":"362","author":"Denault","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0002-8703(03)00445-9","article-title":"Left ventricular wall stress as a direct correlate of cardiomyocyte apoptosis in patients with severe dilated cardiomyopathy","volume":"146","author":"Di Napoli","year":"2003","journal-title":"Am Heart J"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2004.07.004_bib24","first-page":"I-567","article-title":"Characterization of human urotensin-II as the most potent vasoconstrictor identified","volume":"100","author":"Douglas","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1471-4892(03)00012-2","article-title":"Human urotensin-II as a novel cardiovascular target: \u201cheart\u201d of the matter or simply a fishy \u201ctail\u201d?","volume":"3","author":"Douglas","year":"2003","journal-title":"Curr Opin Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2004.07.004_bib26","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1097\/00005344-200036051-00051","article-title":"Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate","volume":"36","author":"Douglas","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib27","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/sj.bjp.0703690","article-title":"Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey","volume":"131","author":"Douglas","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib28","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/S0140-6736(02)08831-1","article-title":"Congestive heart failure and expression of myocardial urotensin II","volume":"359","author":"Douglas","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.tips.2003.12.005","article-title":"From \u2018gills to pills\u2019: urotensin-II as a regulator of mammalian cardiorenal function","volume":"25","author":"Douglas","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1006\/bbrc.2001.5946","article-title":"Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium","volume":"289","author":"Dschietzig","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0167-0115(02)00158-1","article-title":"Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure","volume":"110","author":"Dschietzig","year":"2002","journal-title":"Regul Pept"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib32","first-page":"183","article-title":"Cardiac fibroblasts: function, regulation of gene expression, and phenotypic modulation","volume":"87","author":"Eghbali","year":"1992","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1006\/jmcc.2000.1125","article-title":"Unresolved issues regarding the role of apoptosis in the pathogenesis of ischemic injury and heart failure","volume":"32","author":"Els\u00e4sser","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.bjp.0704671","article-title":"Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey","volume":"136","author":"Elshourbagy","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib35","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1021\/jm0111043","article-title":"Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II","volume":"45","author":"Flohr","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.jhh.1001694","article-title":"The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target?","volume":"18","author":"Freestone","year":"2004","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib37","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/sj.bjp.0704051","article-title":"Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats","volume":"132","author":"Gardiner","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib38","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1139\/y03-122","article-title":"Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats","volume":"82","author":"Gendron","year":"2004","journal-title":"Can J Physiol Pharm"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJM199507273330403","article-title":"Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension","volume":"333","author":"Giaid","year":"1995","journal-title":"New Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib40","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"New Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1476-5381.1987.tb09000.x","article-title":"Complex effects of Gillichthys urotensin II on rat aortic strips","volume":"91","author":"Gibson","year":"1987","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib42","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.2042-7158.1988.tb06298.x","article-title":"The influence of urotensin II on calcium flux in rat aorta","volume":"40","author":"Gibson","year":"1988","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib43","first-page":"276","article-title":"Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease","volume":"5","author":"Gilbert","year":"2004","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0024-3205(01)01101-8","article-title":"Human urotensin II increases coronary perfusion pressure in the isolated rat heart. Potentiation by nitric oxide synthase and cyclooxygenase inhibition","volume":"69","author":"Gray","year":"2001","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib45","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1021\/jm025549i","article-title":"A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge","volume":"45","author":"Grieco","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib46","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/00005344-199322008-00016","article-title":"Intracellular localization of membrane-bound endothelin-converting enzyme from rat lung","volume":"22","author":"Gui","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib47","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1006\/jmcc.2002.2037","article-title":"Calcium cycling in congestive heart failure","volume":"34","author":"Hasenfuss","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib48","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1161\/01.CIR.99.5.641","article-title":"Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium","volume":"99","author":"Hasenfuss","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1139\/y03-004","article-title":"Effect of human urotensin-II infusion on hemodynamics and cardiac function","volume":"81","author":"Hassan","year":"2003","journal-title":"Can J Physiol Pharm"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0168-8278(02)00295-7","article-title":"Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension","volume":"37","author":"Heller","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib51","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1074\/jbc.270.16.9517","article-title":"Proparathyroid hormone is preferentially cleaved to parathyroid hormone by the prohormone convertase furin","volume":"270","author":"Hendy","year":"1995","journal-title":"J Biol Chem"},{"issue":"Suppl. II","key":"10.1016\/j.pharmthera.2004.07.004_bib52","first-page":"62","article-title":"Two isoforms of the novel urotensin-II receptor, GPR14, differ in their capacity to mediate intracellular inositol phosphate accumulation","volume":"104","author":"Herold","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib53","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/01.CIR.103.10.1378","article-title":"Effects of urotensin II in human arteries and veins of varying caliber","volume":"103","author":"Hillier","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib54","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/path.1447","article-title":"Detection of apoptosis using in situ markers for DNA strand breaks in the failing human heart. Fact or epiphenomenon?","volume":"201","author":"Hughes","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib55","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0196-9781(97)00245-3","article-title":"The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32","volume":"18","author":"Hunt","year":"1997","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib56","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1161\/hc4901.102568","article-title":"ACC\/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary","volume":"104","author":"Hunt","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib57","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1056\/NEJM199910213411706","article-title":"Signaling pathways for cardiac hypertrophy and failure","volume":"341","author":"Hunter","year":"1999","journal-title":"New Engl J Med"},{"issue":"Suppl. A","key":"10.1016\/j.pharmthera.2004.07.004_bib58","first-page":"408","article-title":"Urotensin-II in patients with coronary artery disease","volume":"19","author":"Huynh","year":"2003","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib59","first-page":"R361","article-title":"Contraction of major artery segments of rat by fish neuropeptide urotensin II","volume":"252","author":"Itoh","year":"1987","journal-title":"Am J Physiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib60","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0014-2999(88)90042-8","article-title":"Functional receptors for fish neuropeptide urotensin II in major rat arteries","volume":"149","author":"Itoh","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(01)00157-7","article-title":"Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension","volume":"92","author":"Jeffery","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib62","doi-asserted-by":"crossref","first-page":"23277","DOI":"10.1074\/jbc.271.38.23277","article-title":"Phosphorylation specificities of protein kinase C isozymes for bovine cardiac troponin I and troponin T and sites within these proteins and regulation of myofilament properties","volume":"271","author":"Jideama","year":"1996","journal-title":"J Biol Chem"},{"issue":"Suppl. IV","key":"10.1016\/j.pharmthera.2004.07.004_bib63","first-page":"IV-145","article-title":"Urotensin II and cardiomyocyte hypertrophy: inflammatory mediators and effect of selective U-II receptor antagonism","volume":"108","author":"Johns","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568006033337276","article-title":"Remodelling of the myocardium and potential targets in the collagen degradation and synthesis pathways","volume":"3","author":"Jugdutt","year":"2003","journal-title":"Curr Drug Targets Cardiovasc Haematol Disord"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib65","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/0003-4975(95)00718-0","article-title":"Atrial fibrillation after coronary artery bypass grafting is associated with sympathetic activation","volume":"60","author":"Kalman","year":"1995","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib66","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0167-5273(02)00182-1","article-title":"Do results of the ENABLE (Endothelin antagonist bosentan for lowering cardiac events in heart failure) study spell the end for non-selective endothelin antagonism in heart failure?","volume":"85","author":"Kalra","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib67","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates","volume":"82","author":"Kannel","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0014-2999(00)00506-9","article-title":"Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries","volume":"402","author":"Katano","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib69","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00001573-199705000-00007","article-title":"Mechanisms and implications of endothelial dysfunction in congestive heart failure","volume":"12","author":"Katz","year":"1997","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib70","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/BF00173215","article-title":"Both \u03b21- and \u03b22-adrenoceptors mediate catecholamines-evoked arrhythmias in isolated human right atrium","volume":"348","author":"Kaumann","year":"1993","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib71","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/01.ATV.20.10.2233","article-title":"High plasma serotonin levels in primary pulmonary hypertension: effect of long-term epoprostenol (prostacyclin) therapy","volume":"20","author":"K\u00e9reveur","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib72","doi-asserted-by":"crossref","first-page":"C406","DOI":"10.1152\/ajpcell.1993.265.2.C406","article-title":"PKC-mediated redistribution of mitogen-activated protein kinase during smooth muscle cell activation","volume":"265","author":"Khalil","year":"1993","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib73","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1002\/1521-3773(20020816)41:16<2940::AID-ANIE2940>3.0.CO;2-M","article-title":"Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model","volume":"41","author":"Kinney","year":"2002","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib74","doi-asserted-by":"crossref","first-page":"9897","DOI":"10.1074\/jbc.275.14.9897","article-title":"Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility","volume":"275","author":"Kitazawa","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib75","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/01.CIR.0000110644.92116.91","article-title":"Endothelin expression and the progression of heart failure exemplifying the vagaries of therapeutic development","volume":"109","author":"Konstam","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib76","first-page":"75P","article-title":"Urotensin-II is a potent constrictor of human atherosclerotic coronary arteries with immunoreactive peptide localized to the atherosclerotic plaque","volume":"134","author":"Kuc","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib77","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijcard.2003.05.008","article-title":"Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy","volume":"94","author":"Lapp","year":"2004","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib78","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1007\/BF02087701","article-title":"Trypsin activity. A new marker of acute alcoholic pancreatitis","volume":"39","author":"Le Moine","year":"1994","journal-title":"Dig Dis Sci"},{"issue":"Suppl. II","key":"10.1016\/j.pharmthera.2004.07.004_bib79","first-page":"II-113","article-title":"Human urotensin II causes vasoconstriction in the human skin microcirculation","volume":"102","author":"Leslie","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib80","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study","volume":"322","author":"Levy","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib81","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1469-7793.1998.871bp.x","article-title":"Possible involvement of the novel CPI-17 protein in protein kinase C signal transduction of rabbit arterial smooth muscle","volume":"508","author":"Li","year":"1998","journal-title":"J Physiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib82","first-page":"193","article-title":"Activation of calcineurin in human heart ventricle by endothelin-1, angiotensin II and urotensin II","volume":"37","author":"Li","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib83","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1161\/01.CIR.91.11.2844","article-title":"Molecular bases of the acute coronary syndromes","volume":"91","author":"Libby","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib84","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1358\/mf.2003.25.7.778094","article-title":"Role of intracardiac renin-angiotensin-aldosterone system in extracellular matrix remodeling","volume":"25","author":"Lijnen","year":"2003","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib85","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/6430","article-title":"Calcineurin and human heart failure","volume":"5","author":"Lim","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib86","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1161\/01.CIR.0000121326.69153.98","article-title":"Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure","volume":"109","author":"Lim","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib87","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00004872-200301000-00026","article-title":"Central cardiovascular action of urotensin II in conscious rats","volume":"21","author":"Lin","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib88","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/01.CIR.0000056033.16159.48","article-title":"Drug therapy and heart failure prevention","volume":"107","author":"Linseman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib89","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1006\/bbrc.1999.1796","article-title":"Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14","volume":"266","author":"Liu","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib90","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/01.CIR.102.4.470","article-title":"Left ventricular hypertrophy: pathogenesis, detection, and prognosis","volume":"102","author":"Lorell","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib91","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/S0196-9781(02)00104-3","article-title":"Cardiovascular effects of urotensin II in different brain areas","volume":"23","author":"Lu","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib92","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","article-title":"Hemodynamic and neurohumoral effects of selective endothelin A (ETA) receptor blockade in chronic heart failure: the heart failure ETA receptor blockade trial (HEAT)","volume":"106","author":"L\u00fcscher","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib93","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.bjp.0703314","article-title":"Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat","volume":"130","author":"MacLean","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib94","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00004872-199501000-00019","article-title":"Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation","volume":"13","author":"Maggi","year":"1995","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib95","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bjp.0703601","article-title":"Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1","volume":"131","author":"Maguire","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib96","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1006\/geno.1995.9996","article-title":"Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors","volume":"29","author":"Marchese","year":"1995","journal-title":"Genomics"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib97","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/00004872-200112000-00011","article-title":"Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues","volume":"19","author":"Matsushita","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib98","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1159\/000136932","article-title":"Pharmacological effects of urotensins: I. Regional vascular effects of urotensin I and II in the rat","volume":"13","author":"Medakovic","year":"1975","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib99","doi-asserted-by":"crossref","first-page":"13893","DOI":"10.1073\/pnas.95.23.13893","article-title":"Transient cardiac expression of constitutively active G\u03b1q leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways","volume":"95","author":"Mende","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF00788869","article-title":"Influence of endothelin 1 on human atrial myocardium-myocardial function and subcellular pathways","volume":"91","author":"Meyer","year":"1996","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib101","doi-asserted-by":"crossref","first-page":"16396","DOI":"10.1016\/S0021-9258(18)42016-9","article-title":"Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen","volume":"267","author":"Molloy","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib102","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00109-003-0451-x","article-title":"Tuning smooth muscle contraction by molecular motors","volume":"81","author":"Morano","year":"2003","journal-title":"J Mol Med"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib103","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1152\/jappl.2001.91.2.953","article-title":"Cross-bridge regulation by thin filament-associated proteins","volume":"91","author":"Morgan","year":"2001","journal-title":"J Appl Physiol"},{"issue":"Suppl. II","key":"10.1016\/j.pharmthera.2004.07.004_bib104","first-page":"II-26","article-title":"Urotensin II inhibits left ventricular and myocytes contractile performance and [Ca2+]i transient: normal vs CHF","volume":"106","author":"Morimoto","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib105","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/01.ATV.18.10.1541","article-title":"Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein","volume":"18","author":"Moriwaki","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib106","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/bj3270625","article-title":"Furin: a mammalian subtilisin\/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins","volume":"327","author":"Nakayama","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib107","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/01.RES.86.4.377","article-title":"Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart","volume":"86","author":"Neri Serneri","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib108","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/01.CIR.0000044388.19119.02","article-title":"Plasma urotensin in human systolic heart failure","volume":"106","author":"Ng","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib109","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/bbrc.1993.1617","article-title":"Phosphorylation of cardiac myosin light chain 2 by protein kinase C and myosin light chain kinase increases Ca2+-stimulated actomyosin MgATPase activity","volume":"193","author":"Noland","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jacc.2003.08.050","article-title":"Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization","volume":"43","author":"Norhammar","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib111","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/14081","article-title":"Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction","volume":"1","author":"Nothacker","year":"1999","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib112","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1523\/JNEUROSCI.06-09-02730.1986","article-title":"Cloning and sequence analysis of cDNAs encoding precursors of urotensin II-alpha and -gamma","volume":"6","author":"Ohsako","year":"1986","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib113","series-title":"FEBS Special Meeting, July Proceedings","article-title":"Atypical regulation of the urotensin-II receptor","author":"Onan","year":"2003"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib114","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1210\/me.2003-0309","article-title":"Urotensin-II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases","volume":"18","author":"Onan","year":"2004","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0014-2999(00)00672-5","article-title":"Human urotensin II mediates vasoconstriction via an increase in inositol phosphates","volume":"406","author":"Opgaard","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib116","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1073\/pnas.97.2.931","article-title":"Overexpression of angiotensin II type 1 receptor in cardiomyocytes induces cardiac hypertrophy and remodeling","volume":"97","author":"Paradis","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib117","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1472-8206.2001.00032.x","article-title":"Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II","volume":"15","author":"Paysant","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib118","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1073\/pnas.77.8.5021","article-title":"Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes","volume":"77","author":"Pearson","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib119","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000015516","article-title":"Assignment of the GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization","volume":"88","author":"Protopopov","year":"2000","journal-title":"Cytogenet Cell Genet"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00380-003-0739-3","article-title":"The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting","volume":"19","author":"Qi","year":"2004","journal-title":"Heart Vessels"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib121","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/01.CIR.0000068316.53218.49","article-title":"\u03b2-Blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure","volume":"107","author":"Reiken","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib122","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(02)09709-X","article-title":"Plasma urotensin II in heart failure","volume":"360","author":"Richards","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib123","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1161\/01.CIR.0000016044.19527.96","article-title":"Calcineurin in human heart hypertrophy","volume":"105","author":"Ritter","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib124","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/01.RES.84.8.891","article-title":"Evidence for intracellular endothelin-converting enzyme-2 expression in cultured human vascular endothelial cells","volume":"84","author":"Russell","year":"1999","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00210-004-0876-y","article-title":"Cardiovascular actions of human urotensin II\u2014considerations for hypertension","volume":"369","author":"Russell","year":"2004","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib126","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cardiores.2004.05.009","article-title":"Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart","volume":"63","author":"Russell","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib127","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/01.RES.83.3.314","article-title":"Human endothelial cell storage granules: a novel intracellular site for isoforms of the endothelin-converting enzyme","volume":"83","author":"Russell","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib128","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.bjp.0703811","article-title":"Cardiostimulant effects of urotensin-II in human heart in vitro","volume":"132","author":"Russell","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib129","doi-asserted-by":"crossref","first-page":"H1576","DOI":"10.1152\/ajpheart.00217.2003","article-title":"Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure","volume":"285","author":"Russell","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.104.065425","article-title":"Urotensin-II converting enzyme activity of furin and trypsin in human cells in vitro","volume":"310","author":"Russell","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib131","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/frne.1998.0164","article-title":"Proadrenomedullin-derived peptides","volume":"19","author":"Samson","year":"1998","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib132","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/hh1101.092034","article-title":"Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase","volume":"88","author":"Sauzeau","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib133","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s00216-003-2211-8","article-title":"Detection of protease activities with the mass-spectrometry-assisted enzyme-screening (MES) system","volume":"377","author":"Schl\u00fcter","year":"2003","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib134","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0165-6147(03)00079-8","article-title":"A central role of EGF receptor transactivation in angiotensin II-induced cardiac hypertrophy","volume":"24","author":"Shah","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib135","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/002215540205000702","article-title":"Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma","volume":"50","author":"Shenouda","year":"2002","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib136","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-2001-15414","article-title":"Inhibition of insulin release by urotensin II\u2014a study on the perfused rat pancreas","volume":"33","author":"Silvestre","year":"2001","journal-title":"Horm Metab Res"},{"issue":"Suppl. 5","key":"10.1016\/j.pharmthera.2004.07.004_bib137","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-2828(86)80460-6","article-title":"Dual trophic effects of the alpha 1-adrenergic receptor in cultured neonatal rat heart muscle cells","volume":"18","author":"Simpson","year":"1986","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib138","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1152\/physrev.00023.2003","article-title":"Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase","volume":"83","author":"Somlyo","year":"2003","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib139","first-page":"S024","article-title":"A radioimmunoassay to detect urotensin II in the plasma of rat models of hypertension","volume":"544P","author":"Song","year":"2002","journal-title":"J Physiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib140","first-page":"107","article-title":"Effects of single bolus urotensin II injection on renal function in anaesthetised rats","volume":"552P","author":"Song","year":"2003","journal-title":"J Physiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib141","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1388-9842(03)00007-2","article-title":"Endothelin receptor antagonists in heart failure\u2014a refutation of a bold conjecture?","volume":"5","author":"Spieker","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib142","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.ATV.20.5.1177","article-title":"Natural history and histological classification of atherosclerotic lesions","volume":"20","author":"Stary","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib143","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.92.5.1355","article-title":"A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis","volume":"92","author":"Stary","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib144","doi-asserted-by":"crossref","first-page":"H925","DOI":"10.1152\/ajpheart.2001.280.2.H925","article-title":"Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries","volume":"280","author":"Stirrat","year":"2001","journal-title":"Am J Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib145","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s001090050275","article-title":"Cellular mechanisms of cardiac hypertrophy","volume":"76","author":"Sugden","year":"1998","journal-title":"J Mol Med"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib146","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1254\/jjp.88.359","article-title":"Cardiac effects of a selective Rho-associated kinase inhibitor, Y-27632, assessed in canine isolated, blood-perfused heart preparations","volume":"88","author":"Sugiyama","year":"2002","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib147","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbrc.2003.09.102","article-title":"Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain","volume":"310","author":"Sugo","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib148","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0014-5793(90)80995-U","article-title":"Endothelin stimulates hypertrophy and contractility of neonatal cardiac myocytes in a serum-free medium","volume":"268","author":"Suzuki","year":"1990","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib149","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1006\/bbrc.1995.1563","article-title":"A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia","volume":"209","author":"Tal","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib150","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0024-3205(02)02346-9","article-title":"Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling","volume":"72","author":"Tamura","year":"2003","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib151","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1254\/jphs.94.376","article-title":"Mechanism of human urotensin II-induced contraction in rat aorta","volume":"94","author":"Tasaki","year":"2004","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib152","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/hh0202.104109","article-title":"Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor","volume":"90","author":"Thomas","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib153","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1213\/01.ANE.0000086723.97421.BC","article-title":"A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study","volume":"97","author":"Thompson","year":"2003","journal-title":"Anesth Analg"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib154","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0140-6736(01)06002-0","article-title":"Role of urotensin II in patients on dialysis","volume":"358","author":"Totsune","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/CS20020271","article-title":"Increased plasma urotensin II levels in patients with diabetes mellitus","volume":"104","author":"Totsune","year":"2003","journal-title":"Clin Sci"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib156","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib157","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.RES.0000084382.64418.BC","article-title":"Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy","volume":"93","author":"Tzanidis","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib158","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.cardiores.2003.11.014","article-title":"Metabolic remodeling of the failing heart: the cardiac burn-out syndrome?","volume":"61","author":"Van Bilsen","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib159","doi-asserted-by":"crossref","first-page":"16066","DOI":"10.1016\/S0021-9258(18)41966-7","article-title":"Polar secretion of endothelin-1by cultured endothelial cells","volume":"267","author":"Wagner","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib160","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1161\/01.CIR.103.20.2441","article-title":"Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure","volume":"103","author":"Wallhaus","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib161","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/hc2601.092848","article-title":"Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells","volume":"104","author":"Watanabe","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib162","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/00004872-200112000-00012","article-title":"Synergistic effect of urotensin II with seretonin on vascular smooth muscle cell proliferation","volume":"19","author":"Watanabe","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib163","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1291\/hypres.25.311","article-title":"Antioxidant N-acetylcysteine inhibits vasoactive agents-potentiated mitogenic effect of mildly oxidized LDL on vascular smooth muscle cells","volume":"25","author":"Watanabe","year":"2002","journal-title":"Hypertens Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib164","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1161\/01.HYP.0000084633.85427.E6","article-title":"Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions","volume":"42","author":"Watson","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib165","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s00125-003-1145-1","article-title":"Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects","volume":"46","author":"Wenyi","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib166","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0008-6363(01)00485-0","article-title":"High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man","volume":"53","author":"Wilkinson","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib167","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1050-1738(01)00111-6","article-title":"The oxidative modification hypothesis of atherosclerosis: does it hold for humans?","volume":"11","author":"Witztum","year":"2001","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib168","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1023\/A:1011401825680","article-title":"The role of interleukin-6 in the failing heart","volume":"6","author":"Wollert","year":"2001","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib169","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0092-8674(94)90425-1","article-title":"ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1","volume":"78","author":"Xu","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib170","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s380-002-8319-2","article-title":"Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium","volume":"16","author":"Zhang","year":"2002","journal-title":"Heart Vessels"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib171","doi-asserted-by":"crossref","first-page":"F2792","DOI":"10.1152\/ajprenal.00342.2002","article-title":"Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney","volume":"285","author":"Zhang","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib172","first-page":"442","article-title":"Effects of urotensin II on isolated rat hearts under normal perfusion and ischemia reperfusion","volume":"55","author":"Zhou","year":"2003","journal-title":"Sheng Li Xue Bao"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib173","doi-asserted-by":"crossref","first-page":"H830","DOI":"10.1152\/ajpheart.00406.2003","article-title":"Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a \u201cvasoconstrictor\u201d with a unique hemodynamic profile","volume":"286","author":"Zhu","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib174","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1081\/RRS-120014593","article-title":"Urotensin II mediates ERK1\/2 phosphorylation and proliferation in GPR14-transfected cell lines","volume":"22","author":"Ziltener","year":"2002","journal-title":"J Recept Signal Transduct Res"},{"key":"10.1016\/j.pharmthera.2004.07.004_bib175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0014-5793(01)03015-0","article-title":"Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats","volume":"508","author":"Zou","year":"2001","journal-title":"FEBS Lett"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725804001019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725804001019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T09:28:23Z","timestamp":1682760503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725804001019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":176,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0163725804001019"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2004.07.004","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}